Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 292Urinary Bladder Neoplasms 39Neoplasm Metastasis 35Carcinoma, Non-Small-Cell Lung 24Carcinoma, Transitional Cell 23Neoplasms 21Breast Neoplasms 20Lung Neoplasms 13Carcinoma, Renal Cell 13Ovarian Neoplasms 12Stomach Neoplasms 11Squamous Cell Carcinoma of Head and Neck 11Non-Muscle Invasive Bladder Neoplasms 10Melanoma 9Small Cell Lung Carcinoma 7Salivary Gland Neoplasms 7Prostatic Neoplasms, Castration-Resistant 7Head and Neck Neoplasms 7Esthesioneuroblastoma, Olfactory 7Esophageal Neoplasms 7Colorectal Neoplasms 7Urethral Neoplasms 6Uterine Cervical Neoplasms 5Triple Negative Breast Neoplasms 5Prostate Cancer Metastatic 5Pancreatic Neoplasms 5Metastatic Castration-resistant Prostate Cancer 5Kidney Neoplasms 5Adenocarcinoma 5Sarcoma 4

Interventions

Blood Specimen Collection 32-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 3Surveys and Questionnaires 2Prednisone 2Positron-Emission Tomography 2Magnetic Resonance Imaging 2Injections 2vistusertib 1technetium 99m 1-(1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)-2-((1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)methyl)-9,14-dioxo-2,8,13,15-tetraazaoctadecane-7,12,16,18-tetracarboxylic acid) 1pembrolizumab 1lortalamine 1ioflupane 1gossypol acetic acid 1carbon-11 acetate 1abiraterone 1Waiting Lists 1Urine Specimen Collection 1Urination 1Transcutaneous Electric Nerve Stimulation 1Therapeutics 1Specimen Handling 1Referral and Consultation 1Prostatectomy 1Preoperative Exercise 1Positron Emission Tomography Computed Tomography 1Pluvicto 1Observation 1Music Therapy 1Multiparametric Magnetic Resonance Imaging 1Mitomycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Disease × Docetaxel × Genitourinary × Clear all
NCT00571675 2010-11-09

A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)

Ascenta Therapeutics

Phase 2 Completed
220 enrolled
Genitourinary

Disease, Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡